APOC3

Assets acting on this target.

Class
APOC3 siRNA

Apolipoprotein C-III (APOC3) is a small protein made mainly in the liver and carried on triglyceride-rich lipoproteins such as chylomicrons and very-low-density lipoprotein (VLDL). It acts as a natural brake on the clearance of these particles: it inhibits lipoprotein lipase, the enzyme that breaks down triglycerides in the bloodstream, and interferes with receptor-mediated uptake of lipoprotein remnants by the liver. Because of this, higher APOC3 levels are associated with higher circulating triglycerides, while genetic loss of APOC3 function is associated with low triglycerides and reduced cardiovascular risk. This has made APOC3 an attractive target for lowering severely elevated triglycerides, particularly in familial chylomicronemia syndrome, where triglyceride accumulation can cause recurrent, dangerous pancreatitis, and more broadly in hypertriglyceridemia linked to cardiovascular disease. Therapeutic strategies aim to reduce the amount of APOC3 protein produced or block its activity, thereby removing the brake on triglyceride clearance and restoring more normal lipid handling. Approaches under investigation include RNA-targeting molecules that reduce hepatic APOC3 production, gene-editing approaches intended to permanently silence the gene, and small molecules that may modulate its function directly. Across these approaches, the shared rationale is the same: lowering APOC3 activity to improve clearance of triglyceride-rich lipoproteins.

By indication

Related mechanisms

APOC3 drugs compared

8 drugs, stage by indication
8 drugs acting on APOC3: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
OlezarsenTryngolzaIonis Pharmaceuticals, Swedish Orphan Biovitrum AB (publ), Theratechnologiesantisense oligonucleotideApprovedApproved in Familial Chylomicronemia Syndrome; Approved in Severe Hypertriglyceridemia; Phase 3 in Hypertriglyceridemia
PlozasiranRedemploArrowhead Pharmaceuticals, SanofiRNAi (siRNA)ApprovedApproved in Familial Chylomicronemia Syndrome; Phase 3 in Hypertriglyceridemia; Phase 3 in Severe Hypertriglyceridemia
HRS-7249Jiangsu Hengrui PharmaceuticalsRNAi (siRNA)Phase 2Phase 2 in Hypertriglyceridemia; Phase 2 in Severe Hypertriglyceridemia
ION775Ionis PharmaceuticalsRNAi (siRNA)Phase 2Phase 2 in Hypertriglyceridemia; Phase 2 in Severe Hypertriglyceridemia
RBD5044Suzhou Ribo Life ScienceRNAi (siRNA)Phase 2Phase 2 in Hypertriglyceridemia
RN0361Rona TherapeuticsRNAi (siRNA)Phase 1/2Phase 1/2 in Hypertriglyceridemia
CS-121CorrectSequence Therapeuticsgene editing (base editing)Phase 1Phase 1 in Familial Chylomicronemia Syndrome; Phase 1 in Severe Hypertriglyceridemia
Kylo-12Kylonova (Xiamen) Biopharma, Sino BiopharmaceuticalRNAi (siRNA)Phase 1Phase 1 in Hypertriglyceridemia

← all mechanisms